You are here

Our science / Clinical Trials / Find a Trial / NCT01425138

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

Back to Search Print Save as PDF Bookmark Trial

NCT01425138

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Randomized controlled clinical trials of treatments for moderate-to-severe plaque
psoriasis.

- Trials had to evaluate at least one of the following: Physician's Global Assessment
(PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Observational studies

- Trials that did not report the Physician's Global Assessment (PGA),

- Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

NCT01425138
Pfizer
Completed
Systematic Review And Meta-Analysis Of Psoriasis Treatments.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Chronic Plaque Psoriasis
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
NCT02969018
All Genders
18+
Years
Multiple Sites
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
NCT03210961
All Genders
18+
Years
Anaheim, California
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
NCT03469336
All Genders
18+
Years
Hamburg,
Plaque Psoriasis Patients
An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
NCT01557283
All Genders
18+
Years
Leuven,
Systematic Review And Meta-Analysis Of Psoriasis Treatments.
Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis
This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.
This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Moderate-to-severe plaque psoriasis published trials.
Psoriasis
Not Provided
Psoriasis
Published data on moderate-to-severe plaque psoriasis.
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
  • Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

  • Trials that did not report the Physician's Global Assessment (PGA),
  • Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01425138
A3921142
No
Not Provided
Not Provided
Pfizer
Pfizer
University of Connecticut School of Pharmacy and Hartford Hospital
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now